Difference between revisions of "Bupropion-moclobemide"

From Psychiatrienet
Jump to: navigation, search
 
(9 intermediate revisions by 3 users not shown)
Line 3: Line 3:
 
| to = moclobemide  
 
| to = moclobemide  
 
| stop =  
 
| stop =  
* Gradually reduce dosage of bupropion to a maximum of 150 mg/ day.
+
{{StopBupropion}}
* When a dosage of 150 mg/day is reached, stop administration.
 
 
| start =  
 
| start =  
* '''Day 1-7:''' wash-out period of one week is necessary.
+
{{Startmoclo}}
* '''Day 8:''' start normal dosage of moclobemide after this week, 300 mg/day.
+
| info =
 
 
 
  }}
 
  }}

Latest revision as of 15:03, 8 March 2024

Bupropion
Type Antidepressant
Group other
links
ATC-code N06AX12
Medscape Bupropion
PubChem 444
PubMed Bupropion
Kompas (Dutch) Bupropion
Wikipedia Bupropion
Moclobemide
Type Antidepressant
Group MAO-I
links
Medscape Moclobemide
PubChem 4235
PubMed Moclobemide
Kompas (Dutch) Moclobemide
Wikipedia Moclobemide

Switch medication from bupropion to moclobemide.[1] [2]

Nietinrijdenbord.png Stop bupropion
  • Day 1: Stop bupropion.
  • bupropion can be stopped abruptly for every dosage.[3]
Eenrichtingbord.png Start moclobemide
  • Start with moclobemide 300 mg in 2-3 doses
  • After a week the dosage of moclobemide can be increased.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
  3. Multidisciplinair document Afbouwen Overige Antidepressiva 2023
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.